ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,187.70
0.13%
US Tech 100
17,617.63
0.04%
다우존스 지수
38,884.26
0.08%
Bitcoin
62,568.64
0.38%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Cardiff Oncology Inc (CRDF)

  7. Cardiff Oncology Inc (CRDF) 뉴스

CRDF

Cardiff Oncology (CRDF)

Cardiff Oncology Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:CRDF
일자시간출처헤드라인심볼기업
2024/05/0305:05GlobeNewswire Inc.Cardiff Oncology Reports First Quarter 2024 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
2024/04/2605:05GlobeNewswire Inc.Cardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
2024/04/0905:05GlobeNewswire Inc.Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical StudyNASDAQ:CRDFCardiff Oncology Inc
2024/03/0808:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
2024/03/0808:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
2024/03/0808:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
2024/03/0808:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
2024/03/0706:05GlobeNewswire Inc.Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024NASDAQ:CRDFCardiff Oncology Inc
2024/03/0106:07GlobeNewswire Inc.Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
2024/03/0106:06GlobeNewswire Inc.Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRCNASDAQ:CRDFCardiff Oncology Inc
2024/03/0106:05GlobeNewswire Inc.Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)NASDAQ:CRDFCardiff Oncology Inc
2024/03/0106:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CRDFCardiff Oncology Inc
2024/02/2622:00GlobeNewswire Inc.Cardiff Oncology to Present at the Cowen 44th Annual Health Care ConferenceNASDAQ:CRDFCardiff Oncology Inc
2024/02/2222:00GlobeNewswire Inc.Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
2024/02/0706:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CRDFCardiff Oncology Inc
2024/01/1800:30PR Newswire (US)Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer ResearchNASDAQ:CRDFCardiff Oncology Inc
2024/01/0823:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
2023/11/2106:05PR Newswire (US)Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:CRDFCardiff Oncology Inc
2023/11/0305:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
2023/11/0305:05PR Newswire (US)Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
2023/11/0305:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRDFCardiff Oncology Inc
2023/10/2705:05PR Newswire (US)Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
2023/09/2705:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
2023/09/2705:05PR Newswire (US)Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib MonotherapyNASDAQ:CRDFCardiff Oncology Inc
2023/09/0521:00PR Newswire (US)Cardiff Oncology to Present at Upcoming Investor Conferences in SeptemberNASDAQ:CRDFCardiff Oncology Inc
2023/08/1005:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
2023/08/1005:05PR Newswire (US)Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
2023/08/1005:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRDFCardiff Oncology Inc
2023/08/0805:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
2023/08/0805:05PR Newswire (US)Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer RelationshipNASDAQ:CRDFCardiff Oncology Inc
 검색 관련기사 보기:NASDAQ:CRDF

최근 히스토리

NYSE
DIS
Walt Disney
NASDAQ
AAPL
Apple
NASDAQ
TSLA
Tesla
NASDAQ
AMZN
Amazon.com
NYSE
MCD
McDonalds
AMEX
SPY
SPDR S&P 500
CCOM
SILVER
SILVER
USI
USTECH100
US Tech 100
PM
XAUUSD
Gold vs US Dollar
NYSE
CVX
Chevron
NASDAQ
GOOGL
Alphabet
USOTC
BNPQY
BNP Paribas (QX)
NYSE
AXP
American Express
NYSE
MRK
Merck
FX
USDGBP
US Dollar vs Sterling
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유